Advanced Oncotherapy (LON:AVO) Posts Earnings Results, Misses Expectations By $0.93 EPS

Advanced Oncotherapy (LON:AVO) released its quarterly earnings results on Monday. The company reported GBX (9.83) (($0.12)) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (8.90) (($0.11)) by GBX (0.93) (($0.01)), Bloomberg Earnings reports.

Shares of LON:AVO opened at GBX 26 ($0.32) on Tuesday. Advanced Oncotherapy has a one year low of GBX 20 ($0.25) and a one year high of GBX 44.50 ($0.55). The company has a debt-to-equity ratio of 55.71, a current ratio of 2.16 and a quick ratio of 0.79. The company has a market cap of $79.66 million and a price-to-earnings ratio of -1.86. The firm has a 50 day simple moving average of GBX 26.68 and a 200 day simple moving average of GBX 32.10.

Advanced Oncotherapy Company Profile

Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer.

Recommended Story: How to interpret a stock’s beta number

Receive News & Ratings for Advanced Oncotherapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy and related companies with MarketBeat.com's FREE daily email newsletter.